|
⚲
|
| Keyboard |
| Baker Bros Advisors LP
✚
|
|
|---|---|
| CRD # | 158149 |
| SEC # | 801-73446 |
| CIK # | 0001263508 |
| AUM | 28.15 B (2026-03-27) |
| Employees | 60 (28% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-339-5600 |
| Address | 860 Washington Street, 3rd Floor New York, NY 10014 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Incyte Corp | 2.9 | ||
| BeiGene Ltd | 2.6 | ||
| Insmed Inc | 1.2 | ||
| Synta Pharmaceuticals Corp | 1.1 | ||
| Acadia Pharmaceuticals Inc | 1.0 | ||
| Revolution Medicines Inc | 0.9 | ||
| Celcuity Inc | 0.9 | ||
| Kodiak Sciences Inc | 0.8 | ||
| Kymera Therapeutics Inc | 0.7 | ||
| Summit Therapeutics PLC | 0.7 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | 14159 LP | 2012-02-13 | 17.0 M | |
| HF | 667 LP | 2012-02-13 | 2,337.7 M | |
| HF | Baker Biotech Fund II A LP | 2012-02-13 | 9.4 M | |
| HF | Baker Bros Investments II LP | 2012-02-13 | 1.2 M | |
| HF | Baker Bros Investments LP | 2012-02-13 | 9.8 M | |
| HF | Baker Brothers Life Sciences LP | [2012-02-13] | 25.81 B | |
| Filed 2025-10-14 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Baker/Tisch Investments LP | 2012-02-13 | 11.0 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 2 | 28.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 28.1 |
| By Discretionary | ||
| Discretionary | 2 | 28.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 28.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 28.1 | |
| Total | 2 | 28.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Felix Baker | Executive Officer | 20 | 2 | |
| Julian Baker | Executive Officer | 9 | 2 | |
| Baker Brothers Life Sciences Capital LP | Executive Officer | 8 | 2 | |
| Baker Brothers Life Sciences Capital GP LLC | Executive Officer | 6 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001263508] | |
| 3 | [0001263508] | |
| 4 | [0001263508] | |
| 5 | [0001263508] | |
| SC 13D | [0001263508] | |
| SC 13G | [0001263508] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $11.0B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300QYZVDO3190ER85 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
DBV Technologies SA DBVT
BS Warrant · derivative
|
2026-01-12 | Option exercise | 2,299,656 | $0.00 | |
|
DBV Technologies SA DBVT
BS Warrant · derivative
|
2026-01-12 | Option exercise | 25,005,240 | $0.00 | |
|
DBV Technologies SA DBVT
Second Pre-Funded Warrant · derivative
|
2026-01-12 | Option exercise | 2,299,656 | $0.00 | |
|
DBV Technologies SA DBVT
Second Pre-Funded Warrant · derivative
|
2026-01-12 | Option exercise | 25,005,240 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
Share Option (Right to Buy) · derivative
|
2026-01-02 | Grant | 38,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
Share Option (Right to Buy) · derivative
|
2026-01-02 | Grant | 38,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
American Depositary Shares
|
2026-01-02 | Grant | 19,000 | $0.00 | |
|
Bicycle Therapeutics PLC BCYC
American Depositary Shares
|
2026-01-02 | Grant | 19,000 | $0.00 | |
|
Incyte Corp INCY
Common Stock
|
2025-12-31 | Grant | 328 | $0.00 | |
|
Incyte Corp INCY
Common Stock
|
2025-12-31 | Grant | 328 | $0.00 | |
|
Kodiak Sciences Inc KOD
Common Stock
|
2025-12-18 | Buy | 2,391,268 | $23.00 | 54,999,164 |
|
Kodiak Sciences Inc KOD
Common Stock
|
2025-12-18 | Buy | 217,428 | $23.00 | 5,000,844 |
|
Kymera Therapeutics Inc KYMR
Common Stock
|
2025-12-11 | Buy | 1,838,621 | $86.00 | 158,121,406 |
|
Kymera Therapeutics Inc KYMR
Common Stock
|
2025-12-11 | Buy | 167,192 | $86.00 | 14,378,512 |
|
Denali Therapeutics Inc DNLI
$0.01 Prefunded Warrants · derivative
|
2025-12-11 | Buy | 190,523 | $17.49 | 3,332,247 |
|
Denali Therapeutics Inc DNLI
$0.01 Prefunded Warrants · derivative
|
2025-12-11 | Buy | 2,095,191 | $17.49 | 36,644,891 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 1,213 | $9.07 | 11,002 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 1,186 | $9.07 | 10,757 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 13,386 | $9.07 | 121,411 |
|
Entrada Therapeutics Inc TRDA
Common Stock
|
2025-11-20 | Buy | 13,082 | $9.07 | 118,654 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Gotham Asset Management LLC
✚
|
NY | 30.03 B |
|
Voleon Capital Management LP
✚
|
CA | 29.38 B |
|
Quadrature US Inc
✚
|
NY | 28.80 B |
|
Axiom Investors LLC
✚
|
CT | 28.06 B |
|
Jacobs Levy Equity Management Inc
✚
|
NJ | 28.01 B |
|
Research Affiliates LLC
✚
|
CA | 27.84 B |
|
Anchorage Capital Advisors LP
✚
|
NY | 27.83 B |
|
Kirkoswald Asset Management LLC
✚
|
NY | 27.16 B |
|
Aristotle Pacific Capital LLC
✚
|
CA | 26.76 B |
|
CFI Partners LLC
✚
|
IL | 26.31 B |